Aurinia Pharmaceuticals Inc. (AUPH) Earnings Call Transcripts
Aurinia Pharmaceuticals Inc.'s Latest Earnings Call - June 3, 2026
During the 2026 Annual General Meeting, Aurinia Pharmaceuticals did not provide specific financial results or guidance updates, leaving investors without key performance metrics for the quarter. The absence of earnings details may lead to uncertainty among investors regarding the company's financial health and future prospects. The meeting primarily focused on procedural matters, including the election of board members and the appointment of auditors, rather than substantive financial disclosures.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | (null) |
| EPS | (null) |
| Operating Margin | (null) |
| Shareholder Attendance | 67% (positive) |
Guidance from management
No financial guidance or updates were provided during the meeting, leaving future expectations unclear.
What management said
Hello, and welcome to the 2026 Aurinia Pharmaceuticals Annual General Meeting. The meeting will now come to order. My name is Kevin Tang, and I am Aurinia's Chief Executive Officer. Pursuant to Aurinia's bylaws, I will be acting as Chair of the meeting. I will ask Stephen Robertson, Corporate Secretary, to act as Secretary for this meeting, and I will ask Kyle Gould of Computershare Trust Company of Canada to act as ...
The record date for this meeting was the close of business on April 14, 2026. And I have an affidavit of a representative of Computershare Trust Company of Canada, attesting that the materials prepared in connection with the meeting were delivered in accordance with the Business Corporations Act of Alberta and applicable securities laws to all shareholders of record as of the close of business on April 14, 2026. Ther...
What analysts pressed on
Analysts expressed concern over the lack of financial disclosures during the meeting, questioning the company's transparency and future performance. The absence of revenue and earnings figures could lead to uncertainty in the investment community.
Main topics on the call
- Board of Directors Election — Aurinia successfully elected five directors, including CEO Kevin Tang, for the upcoming term. This was a routine procedural matter with no objections raised, indicating shareholder support for current leadership.
- Appointment of Auditors — PricewaterhouseCoopers LLP was reappointed as auditors until the next annual meeting. This decision was also unopposed, reflecting confidence in the firm's financial oversight.
- Say on Pay Resolution — A nonbinding advisory vote on executive compensation was approved without discussion. This suggests shareholder acceptance of the current compensation structure for executives.
- Lack of Financial Disclosure — The meeting did not include any discussion of financial results or guidance, which could lead to investor concerns regarding transparency and future performance expectations.
Read the full Aurinia Pharmaceuticals Inc. transcript (June 3, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 43 calls on record spanning March 5, 2020 to June 3, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 43 Aurinia Pharmaceuticals Inc. earnings call transcripts on record, spanning March 5, 2020 to June 3, 2026. Based on this history, Aurinia Pharmaceuticals Inc. reports quarterly. The most recent call on file is dated June 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AUPH
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 43
- First call
- March 5, 2020
- Most recent
- June 3, 2026
- Reporting cadence
- quarterly